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Abstract
Preferentially expressed antigen in melanoma (PRAME) has been described as a cancer-testis antigen and is associated with
leukaemias and solid tumours. Here we show that PRAME gene transcription in leukaemic cell lines is rapidly induced by
exposure of cells to bacterial PAMPs (pathogen associated molecular patterns) in combination with type 2 interferon (IFNc).
Treatment of HL60 cells with lipopolysaccharide or peptidoglycan in combination with IFNc resulted in a rapid and transient
induction of PRAME transcription, and increased association of PRAME transcripts with polysomes. Moreover, treatment with
PAMPs/IFNc also modulated the subcellular localisation of PRAME proteins in HL60 and U937 cells, resulting in targeting of
cytoplasmic PRAME to the Golgi. Affinity purification studies revealed that PRAME associates with Elongin B and Elongin C,
components of Cullin E3 ubiquitin ligase complexes. This occurs via direct interaction of PRAME with Elongin C, and PRAME
colocalises with Elongins in the Golgi after PAMP/IFNc treatment. PRAME was also found to co-immunoprecipitate core
histones, consistent with its partial localisation to the nucleus, and was found to bind directly to histone H3 in vitro. Thus,
PRAME is upregulated by signalling pathways that are activated in response to infection/inflammation, and its product may
have dual functions as a histone-binding protein, and in directing ubiquitylation of target proteins for processing in the
Golgi.
Citation: Wadelin FR, Fulton J, Collins HM, Tertipis N, Bottley A, et al. (2013) PRAME Is a Golgi-Targeted Protein That Associates with the Elongin BC Complex and
Is Upregulated by Interferon-Gamma and Bacterial PAMPs. PLoS ONE 8(2): e58052. doi:10.1371/journal.pone.0058052
Editor: William R. Abrams, New York University, United States of America
Received January 5, 2012; Accepted January 30, 2013; Published February 27, 2013
Copyright:  2013 Wadelin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by Leukaemia Lymphoma Research via a clinical training fellowship to FRW (07064). JF was funded by the Royal Pharmaceutical
Society of Great Britain via an Academic Excellence Award to DMH. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: david.heery@nottingham.ac.uk
Introduction
PRAME/MAPE/OIP4 is an atypical cancer-testis antigen
whose expression is associated with leukaemias and a large
proportion of solid tumours (reviewed in [1]). Unlike other
cancer-testis antigens whose expression is restricted to testis, the
PRAME gene shows low level expression in other normal tissues
including endometrium, ovary and placenta [2]. The restricted
expression pattern of PRAME in normal tissues and its
overexpression in tumours renders it a useful marker of minimal
residual disease after chemotherapy, and an attractive target for
immunotherapy, particularly in acute myeloid leukaemia (AML)
and chronic myeloid leukaemia (CML) [2,3,4,5,6,7,8,9,10,11,12].
In PRAME-negative leukaemias the gene can be induced by
demethylating agents [2,13,14], but little else is known regarding
pathways that regulate PRAME expression.
PRAME is a member of a rapidly evolving multigene family,
and encodes a leucine-rich repeat (LRR) protein sharing
structural similarity with Toll-like receptors [1,15]. The extensive
duplication rate of PRAME and other cancer testis antigen genes
is suggestive of roles in chemosensing, reproduction or immunity
[15]. PRAME was originally identified in a yeast two-hybrid
screen for proteins that bind outer membrane proteins of
pathogenic bacteria [16], although until recently there has been
little insight into its functions in mammalian cells. Nuclear
localised PRAME has been implicated in transcriptional repres-
sion via association with retinoic acid receptor complexes [17].
More recently, while this study was in progress, PRAME was
shown to be a chromatin-associated protein enriched at nuclear
factor Y (NFY) target genes, in association with Elongin and
Cullin-2 proteins [18]. However, a large proportion of endog-
enous PRAME protein is observed in the cytoplasmic compart-
ment in different cell lines [1,19]. Given its reported interaction
with bacterial outer membrane proteins [16] and the rapid
evolution of the PRAME multigene family in humans [15],
similar to the Nacht, LRR, PYD domain (NALP) gene family
[20], we hypothesised that PRAME might be regulated by
signalling pathways activated in proinflammatory responses. We
therefore set out to investigate whether PRAME expression is
modulated by signalling molecules such as IFNc or microbial
PAMPs. We also endeavoured to isolate PRAME-interacting
proteins, to provide further insight into its cellular functions.
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Results
Upregulation of PRAME expression by IFNc and bacterial
PAMPs
PRAME protein contains a series of leucine-rich repeats similar
to those found in the LRR protein family and is predicted to be
structurally similar to human Toll-like receptors (TLRs) [1,15].
Unlike the membrane-associated TLRs, PRAME is an intracel-
lular protein found in both the nuclear and cytoplasmic
compartments [1]. TLRs function in innate immunity as sensors
of microbial PAMPs or other ligands, and their expression is
regulated by these molecules and also by IFNc, a proinflammatory
cytokine produced in response to infection. We therefore assessed
whether PRAME expression in leukaemic cells such as HL60 might
be modulated by exposure to lipopolysaccharide (LPS) and IFNc,
either as single inducing agents or in combination. HL60
leukaemic cells have low levels of PRAME transcripts [1], and
are known to express TLR2 and TLR4 [21]. Treatment of HL60
cells with IFNc or LPS alone did not significantly alter the
expression of PRAME (as determined by RT-qPCR – data not
shown). However, as shown in Fig. 1A, a strong increase in
PRAME transcript levels was observed within 1 hour of combined
treatment with LPS and IFNc. This increase was transient as
PRAME levels were lower at 4 hours post-treatment, and restored
to background levels within 24 hours, suggesting that turnover of
PRAME mRNA may be relatively rapid. The induction of PRAME
by LPS/IFNc was inhibited by pre-treating cells with actinomycin
D for one hour prior to addition of LPS/IFNc (Fig. 1B), indicating
that the increase in PRAME levels is due to de novo transcription
rather than altered stability of the transcripts.
To examine whether LPS/IFNc results in increased translation
of PRAME transcripts, polysome gradients were prepared from
extracts of HL60 cells treated or untreated with LPS and IFNc. As
shown in Fig. 1C, within 4 hours post-treatment with LPS/IFNc,
PRAME transcripts were substantially enriched in polysome
fractions, as confirmed by densitometry (lower panels). In contrast,
a control transcript (b-actin) showed little change. These results
indicate that upregulation of PRAME gene expression by LPS/
IFNc in HL60 cells may be achieved not only through increased
transcription, but also effects on translation of PRAME transcripts.
We also assessed whether PRAME expression could be induced
by other microbial PAMPs in addition to LPS. As shown in
Fig. 1A, treatment of HL60 cells with PAMPs such as muramyl
dipeptide (MDP), zymosan A (ZYM) or mannan (MAN) for
different times, either alone or in combination with IFNc, had
relatively little effect on PRAME expression. In contrast, peptido-
glycan (PGN) in combination with IFNc substantially increased
PRAME expression, similar to the LPS/IFNc response. Induction
of PRAME by PGN/IFNc was also transient, with peak levels
observed within 1 hour post-treatment (Fig. 1A). Taken together,
these results indicate that, similar to genes encoding other LRR
proteins such as NALPs and TLRs, PRAME expression in HL60
cells may be rapidly induced by signalling pathways activated in
response to bacterial infection/inflammation.
Subcellular localisation of PRAME is altered by bacterial
PAMPs/IFNc
Endogenous or recombinant PRAME proteins have been
reported to localise to both nuclear and cytoplasmic compartments
in a variety of cell types, including adherent cells [19] and
leukaemic cell lines [1]. Transient transfection of U2OS or
HEK293 cells with recombinant PRAME-EGFP or PRAME-
FLAG revealed both nuclear and cytoplasmic staining, with the
majority of signal (70–80% of total fluorescence) being observed in
the cytoplasm of these cells within 24 hrs of transfection (Fig. 2A).
Staining with a specific antibody recognising PRAME confirmed
the identity of the recombinant PRAME-EGFP and PRAME-
FLAG constructs, in contrast to neighbouring non-transfected cells
which showed negligible endogenous levels of PRAME (Fig. 2A).
In contrast to PRAME-EGFP, EGFP alone showed approximately
equal distribution in the nucleus and cytoplasm whereas co-
transfected PRAME-FLAG was predominantly cytoplasmic
(Fig. 2A, lower panels). These observations are consistent with
suggestions that PRAME is likely to have both nuclear and
cytoplasmic functions, although the distribution between these
compartments may vary in different cell types and conditions.
To determine whether exposure to bacterial PAMPs/IFNc had
any effect on the subcellular localisation of PRAME, we
performed immunofluorescence staining of cells exposed to these
agents, or controls. A longer treatment time (4 hours) was used to
allow for expression of PRAME proteins in the cells. As shown in
Fig. 2B, treatment of HL60 cells with LPS/IFNc (middle panels)
or PGN/IFNc (lower panels) for 4 hours resulted in localisation of
PRAME to large cytoplasmic foci. A similar effect was observed in
the leukaemic cell line U937 in response to LPS/IFNc treatment
(Fig. 2C). Quantitation of PRAME-containing foci in LPS/IFNc-
treated and or control cells revealed a major change in the
subcellular distribution of PRAME in response to LPS/IFNc
treatment (Fig. 2E&F).
The polarised distribution of the PRAME-containing foci,
suggested that these structures may represent the trans Golgi
network, and staining of HL60 cells with the 58K Golgi marker
confirmed that these structures appear to be linked to the Golgi
network and show considerable colocalisation with PRAME
(Fig. 2D). We noted that the nuclei of LPS/IFNc treated HL60
and U937 cells appeared to undergo a morphological change
resulting in ‘kidney’ shaped nuclei being visible after 4 hours
treatment (Fig. 2B&C), and that this phenotype was prevalent in
many of the treated cells, but less obvious in controls (Fig. 2E).
PRAME and the 58K Golgi marker accumulated at the apex of
the invaginated region (Fig. 2D, lower panels). Thus, we conclude
that in HL60 and U937 cells, cytoplasmic PRAME proteins are
targeted to the Golgi network following exposure to LPS/IFNc.
Consistent with this, subcellular localisation prediction algorithms
(PSORT.org) and other sequence analysis resources predict that
PRAME is likely to be a Golgi-targeted protein [22]. Staining of
endogenous PRAME in MCF-7 breast cancer cells also revealed
its association with Golgi-like structures (Fig. 2G).
Functional association of PRAME with Elongin BC
complexes
To further investigate the functions of PRAME, we performed
affinity purification experiments to identify PRAME-associated
proteins. Cleared whole cell lysates of HL60 cells were applied to
GST-PRAME or control GST beads. After extensive washing,
affinity purified proteins were visualised by silver staining,
revealing a number of PRAME-specific bands (Fig. 3A). We
selected two bands in the molecular range 10–20 kDa, which were
among the most abundant and which were clearly absent in the
controls (Fig. 3A). Following gel excision and extraction, these
samples were subjected to reverse phase liquid-chromatography
followed by high mass accuracy mass spectrometry. Polypeptides
were identified using the MASCOT search engine [23]. As shown
in Table 1, the top hits were the human ELB (elongin B) and ELC
(elongin C) proteins. These are components of the E3 ubiquitin
ligase complexes and are implicated in both protein ubiquitylation
and transcription elongation.
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Figure 1. Transcriptional and translational regulation of PRAME by PAMPs/IFNc. (A) RT-qPCR measurements of PRAME gene expression
relative to control GAPDH in HL60 cells in response to treatment with different PAMPs including lipopolysaccharide (LPS), peptidoglycan (PGN),
muramyl dipeptide (MDP), zymosan (ZYM) and mannan (MAN) either alone (PBS) or in combination with IFNc. Numbers on the x-axis indicate the
time in hrs post-treatment. qPCR quantifications were performed in triplicate and the data shown represents the mean of two independent
experiments, with error bars indicating standard deviations. The data is presented as fold induction relative to levels obtained at 0 hr (baseline). (B)
RT-qPCR experiment performed as in (A) showing effect of pre-treatment with actinomycin D (10 mg/ml) or PBS on induction of PRAME transcript in
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To validate these potential interactions, co-immunoprecipita-
tion experiments were performed. As shown in Fig. 3B, endog-
enous ELB and ELC proteins were successfully co-purified from
HEK293 cell extracts in complex with transiently expressed
recombinant PRAME-FLAG-His. Similarly, GST-PRAME, but
not GST alone, was able to purify both ELB and ELC from HL60
whole cell extracts (Fig. 3C). However, incubation of GST-
PRAME with 35 [S]-labelled in vitro translated proteins revealed
that direct interaction occurs between PRAME and ELC, but not
ELB (Fig. 3D). This was confirmed using yeast two hybrid studies,
which detected a strong interaction between LexA-PRAME and
GAL4 activation domain-fused human or C. elegans ELC proteins,
(which share 74% sequence identity), but not ELB (Fig. 3E).
Moreover, this interaction with ELC was disrupted by mutations
(L47D-L49D-Y88D-Y91D) in a conserved region required for
binding of NLP48 [24] (Fig. 3E). No interaction was detected
using ELB, although western blots on yeast cell-free extracts
confirmed the expression of both ELB and ELC constructs
(Fig. 3E). We also detected the Elongin BC-associated protein
Cullin 2 (CUL2) in co-immunoprecipitation experiments using
whole cell extracts from PRAME transfected HEK293 cells
(Fig. 3B). Taken together, these results provide strong evidence for
functional interaction between PRAME and components of the
Elongin/Cullin E3 ubiquitin ligase complexes, consistent with the
recent report from Costessi et al [18]. Our data further suggest that
this is due to direct interaction of PRAME and ELC. Immuno-
fluorescence staining of endogenous ELB and ELC proteins in
HL60 cells revealed their localisation to cytoplasmic structures
resembling Golgi (Fig. 3F). Unlike PRAME, this association of
ELB and ELC with Golgi was not dependent on treatment with
PAMP/IFNc (Fig. 3F). Some nuclear staining of ELB and ELC
was also detected, consistent with proposed roles of these proteins
in transcriptional elongation [24]. Co-staining of LPS/IFNc
treated HL60 cells revealed extensive overlap of ELC and
PRAME in Golgi-like structures, supporting the conclusion that
these proteins colocalise to the Golgi (Fig. 3G). In contrast, CUL2
was found to be almost exclusively nuclear under similar
conditions (Fig. 3F), which may be consistent with the identifica-
HL60 cells by LPS/IFNc (1 hour). (C) Association of PRAME transcripts with polysomes in HL60 cells following treatment with LPS/IFNc for 0 and 4 hrs.
Following cycloheximide treatment and sucrose density centrifugation of HL60 cell lysates, gradients were fractionated with continuous monitoring
at 254 nm, to generate polysome profiles (top panel). RNA extracted from polysome fractions was analysed by Northern blotting and the PRAME
transcripts visualised by phosphoimager (middle panels) and quantified by densitometry (bottom panels). b-actin was used as a control probe.
doi:10.1371/journal.pone.0058052.g001
Figure 2. PRAME localises to the Golgi network following LPS/IFNc treatment. (A) HEK293 cells (upper panels) were transiently transfected
with PRAME-EGFP (green) and stained with a-PRAME antibody (red) to confirm the identity of the overexpressed EGFP fusion protein. U2OS cells
(lower panels) were cotranfected with GFP (green) and PRAME-FLAG (red). Merged images indicate the extent of coincidence of the EGFP and a-
PRAME signals, and nuclear DNA is indicated (blue). The right hand panels are western blots showing detection of GFP or PRAME-EGFP proteins in
whole cell extracts of transfected U2OS cells. (B) Immunostaining of endogenous PRAME in HL60 cells using a-PRAME antibody following treatment
with PBS, LPS/IFNc or PGN/IFNc for 4 hrs. (C) Immunostaining of endogenous PRAME in U937 cells with a-PRAME following treatment with LPS/IFNc
for 0, 1 and 4 hrs. (D) HL60 cells treated with LPS/IFNc for 4 hrs and immunostained with a-Golgi 58K (green) and a-PRAME (red). Merged images
show the extent of colocalisation of both proteins. For immunofluorescence (A–D), nuclear DNA was stained using Hoechst 33258 and images were
captured using a LSM510 confocal laser scanning microscope. (E) Immunostaining of endogenous PRAME in HL60 cells using a-PRAME antibody
following treatment with PBS or LPS/IFNc for 4 hrs. (F) Quantification (n = 60) of the percentage of cells in (E) containing PRAME cytoplasmic foci in
treated cells or controls. (G) Immunostaining of endogenous PRAME in MCF-7 cells using a-PRAME antibody.
doi:10.1371/journal.pone.0058052.g002
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tion of a CUL2/Elongin BC/PRAME complex in nuclear extracts
[18]. Other ubiquitin ligase complexes have been implicated in
trafficking to the Golgi and ER, and it remains possible that
cytoplasmic PRAME can associate with other Cullins such as the
Golgi-targeted CUL3 or CUL7 proteins [25,26].
Interaction of PRAME with histones
In addition to Elongins, the mass spectrometry analysis also
detected histones as putative PRAME binding proteins (Table 1).
Nuclear localised PRAME was recently reported to act as a
coregulator of gene expression, being recruited to a subset of NFY-
Figure 3. PRAME associates with the Elongin BC complex. (A) SDS-PAGE and silver staining showing affinity capture of proteins from HL60
whole cell extracts (WCE) by immobilised GST or GST-PRAME proteins. GST and GST-PRAME proteins are indicated. Putative PRAME-specific bands are
indicated and bands of approximately 12 kDa and 17 kDa were excised for mass spectrometry analysis. (B) Co-immunoprecipitation of PRAME with
Elongin complex components. Whole cell extracts of HEK293 cells transfected with PRAME-FLAG-6xHis (or empty vector control) applied to anti-FLAG
sepharose beads as described in Materials and Methods. After extensive washing, co-purified PRAME and E3 ubiquitin ligase complex components
were detected by western blotting using specific antibodies as indicated. (C) GST-pulldown experiment showing binding of ELB and ELC proteins in
HL60 whole cell extracts to GST or GST-PRAME proteins. The top panel is a Coomassie-stained gel showing the input whole cell extract, and the
purified GST and GST-PRAME proteins. The lower panels are western blots revealing PRAME, ELB and ELC proteins bound to GST proteins. (D) GST-
pulldown experiments revealing interactions of 35 [S]-labelled in vitro translated human ELC (hELC), C.elegans ELC (wELC), C.elegans ELC (L47D-L49D-
Y88D-Y91D) (wELC mutant) and C.elegans ELB proteins with GST or GST-PRAME. (E) Yeast two hybrid assays of LexA-PRAME interactions with GAL4
AD-fused human ELC (hELC) or C.elegans proteins (wELB, wELC, wELC mutant). Western blots of the HA-tagged elongin fusion proteins are also
shown. Reporter activity is expressed as b-galactosidase activity normalised to amount of protein in the extracts. (F) Immunofluorescence staining
showing subcellular localisation of endogenous ELC, ELB and CUL2 proteins in HL60 cells. (G) Immunofluorescence staining showing colocalisation of
endogenous ELC and PRAME proteins in HL60 cells following treatment with LPS/IFNc for 4 hours.
doi:10.1371/journal.pone.0058052.g003
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regulated promoters [18]. While PRAME was demonstrated to
associate with chromatin, it was reported not to interact with DNA
directly, thus the mechanism by which it associates with chromatin
was not established [18]. Immunoprecipitation of epitope-tagged
PRAME from HEK293 whole cell extracts confirmed that all four
core histones can co-immunoprecipitate with PRAME (Fig. 4A).
In addition, GST-pulldown experiments using HL60 whole cell
extracts (Fig. 4B) or core histone preparations (Fig. 4C) also
detected interactions of PRAME with histone H3. Whole cell
extracts may contain histones as nucleosomes, which could
account for the co-precipitation of all four core histones from cell
extracts. However core histone preparations are generally DNA-
free. Therefore, the strong detection of histone H3 in core histone
binding experiments (Fig. 4C) suggests that direct interaction of
PRAME with H3 may enable PRAME to associate with
chromatin.
Discussion
Although PRAME is an important biomarker in certain
haematological malignancies and solid tumours, the regulation
of this gene is poorly understood. Expression of PRAME in
malignant cells is known to be subject to epigenetic regulation, as
we and others have shown that DNA demethylating agents can
induce PRAME in tumours and leukemic cell lines [2,13,14].
However, until now, little else was known regarding the regulation
of PRAME expression. In this study we provide the first evidence
that PRAME may be regulated by signalling pathways involved in
innate immune responses.
Innate immune pathways coordinate appropriate responses to
infection or immunological challenge, and also play a prominent
role in the regulation of haematopoiesis [27,28]. Aberrant activity of
such pathways is associated with myelodysplastic syndromes and
haematological malignancies [28]. For example, chronic inflam-
mation is involved in the origin and progression of certain B-cell
lymphomas and can be mediated through TLRs and other
components of the innate immune system, that are activated
through recognition ofmicrobial PAMPs [29]. Similar pathways are
likely to be involved in progression of myeloid leukaemias. For
example, TLR2 and TLR4 which mediate responses to LPS and
PGN are both activated and upregulated following exposure of
HL60 cells to these agents [21]. Similarly, PGN-mediated activation
of TLR2 and other pathways has been shown to enhance expression
of chemoattractant genes in humanmonocytic leukaemia cells [30].
TLR signalling converges with cytokine signalling and other
pathways to amplify or moderate immune responses. For example,
the proinflammatory cytokine IFNc is produced by macrophages
Table 1. Mass Spectrometry Identification of PRAME Binding
Proteins.
Band Proteins identified Number of peptides Mowse score
1 ELB 6 359
Histone H2B 2 73
2 ELC 6 397
Histone H4 2 108
GST-PRAME binding proteins were affinity purified as described in Materials &
Methods. Bands of approximately 17 kDa and 12 kDa (Fig. 3A) were excised for
mass spectrometry analysis. MS/MS fragmentation data were used to search the
human NCBI database using the MASCOT search engine. Probability-based
Mowse scores are shown.
doi:10.1371/journal.pone.0058052.t001
Figure 4. Binding of PRAME to histone H3. (A) Co-immunopre-
cipitation of endogenous histones with PRAME-FLAG-6xHis isolated
from extracts of transfected HEK293 cells. Input lanes (left panels) show
the presence of endogenous or FLAG-tagged proteins in extracts from
cells transfected with PRAME-FLAG or empty vector. After IP with anti-
FLAG antibody, immunoblots were performed with the antibodies
indicated. (B) GST-pulldown experiment showing association of
histones with GST or GST-PRAME proteins. Whole cell extracts of
HL60 cells were incubated with immobilised GST or GST-PRAME
proteins, and bound proteins separated by SDS-PAGE. Immunoblots
were performed with specific antibodies to detect association of
histones H2A, H2B, H3 and H4 with GST proteins. (C) Direct association
of histones with GST or GST-PRAME proteins. Core histone preparations
were incubated with GST beads. Following extensive washing, bound
histones were separated by SDS-PAGE and revealed by western blotting
using specific antibodies as indicated.
doi:10.1371/journal.pone.0058052.g004
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following intracellular invasion and is known to primemacrophages
to respond to infection [27]. This combination of IFNc with TLR
activation can ensure rapid induction of subsets of proinflammatory
genes. Thus, given the predicted structural similarity of PRAME to
the extracellular LRR domains of TLR2 and TLR4 [1,15], and its
reported ability to bind bacterialOPAproteins [16]we hypothesised
that PRAME might have some role as an intracellular sensor of
invading pathogens. Such an inducible expression profile might
account for its generally low or undetectable levels in normal tissues.
These observations prompted us to investigate whether PRAME
expression might be upregulated in response to microbial PAMPs
and/or IFNc.
Solid tumours can also induce proinflammatory pathways,
producing a microenvironment that favours tumour growth and
proliferation. In addition, tumour-associated leucocytes may
produce cytokines that stimulate tumour growth and angiogenesis
[31]. This can occur through activation of TLRs, or through IFNc
production resulting in activation of downstream effectors such as
nuclear factor kappa B (NFkB), interferon regulatory transcription
factors (IRFs) and signal transducers and activators of transcription
(STATs) [31]. These transcription factors are implicated not only
in the regulation of proinflammatory genes, but also in cancer-
related inflammation and in aberrant gene regulation in tumours
[31]. The mechanism by which PAMP/IFNc treatment induces
PRAME transcription remains to be characterised, but is likely to
involve one or more of these effectors. Interestingly, the proximal
promoter of the PRAME gene contains a number of potential
binding sites for NFkB, IRFs and STATs. Further studies will be
required to characterise the cis and trans acting factors that regulate
PRAME expression.
In addition to the observed effects on de novo transcription
(Fig. 1A&B), treatment of HL60 cells with PAMPs/IFNc also
appeared to increase recruitment of PRAME transcripts into
polysomes (Fig. 1C). This suggests that PRAME may also be
subject to translational regulation, perhaps as a consequence of the
extended 59UTR sequences present in PRAME transcripts [1]. It
remains to be seen whether such insights into the regulation of this
tumour biomarker will enable the manipulation of its expression in
PRAME-negative tumours. As PRAME is undergoing evaluation in
clinical trials as an anti-cancer vaccine target in non-small cell lung
cancer (NCT01159964), its re-activation in tumours might
facilitate their targeting by immunotherapeutics.
Endogenous and overexpressed PRAME proteins were ob-
served in both the nucleus and cytoplasmic compartments in
different cancer cell lines (Fig. 2A–D). In addition to the observed
upregulation of PRAME expression, treatment of HL60 or U937
leukemic cells with PAMPs/IFNc resulted in the accumulation of
cytoplasmic PRAME in Golgi-like structures (Fig. 2B&C). This
was supported by the observed colocalisation of PRAME and the
58K Golgi marker (Fig. 2D). A significant proportion of treated
HL60 cells were found to begin to undergo lobulation of the
nucleus (Fig. 2E). Similar effects on nuclear shape have been
reported for a HL60 cell line undergoing retinoic acid induced
granulopoiesis, with the Golgi juxtapositioned between nuclear
lobes [32]. Interestingly, nuclear lobulation in macrophages
enables them to infiltrate other tissues in response to chemoat-
tractants. Consistent with reports that PRAME is expressed in
breast tumours, [33,34] PRAME was readily detected in MCF7
cells, by immunofluorescence staining (Fig. 2G), where it also
showed a strong association with Golgi-like structures. The
functional consequences of the association of PRAME with the
Golgi remains to be determined, such as whether PRAME plays
role in nuclear lobulation in macrophages or other monocytic
cells.
Due to poor performance of available PRAME antibodies in
detecting endogenous proteins by western blotting, we were
unable to reliably detect an increase in intracellular levels of
soluble PRAME in HL60 cells following IFN/LPS induction. It is
possible that the detection of endogenous PRAME in cell-free
extracts might also be hampered by its retention in the insoluble
fraction of cell lysates, due to increased localisation to Golgi/ER
macromolecular structures.
Using an affinity purification approach to explore the functions
of PRAME through its molecular partners, we identified an
interaction of PRAME with the Elongin/Cullin E3 ubiquitin ligase
complex as confirmed in a range of binding assays and co-
purification experiments (Fig. 3A–G). Co-immunoprecipitation
experiments detected ELB, ELC and CUL2 proteins in complex
with PRAME in HL60 cells. This association of PRAME with the
Elongin/Cullin complex is consistent with a recent report from
Costessi et al. [18], in which a similar complex was identified in
K562 cells, which contain high levels of PRAME protein.
Interestingly, these data are also consistent with a previous study
which noted an interaction between PRAME and the E2 ubiquitin
enzyme UBE2F, in a yeast two-hybrid screen [35]. In our hands,
direct interactions appear to occur between PRAME and ELC,
based on yeast two-hybrid and GST-pulldown assays (Fig. 3D&E),
which is consistent with observations for other complexes involving
LRR and BC box proteins. Thus, as observed for its counterparts
in similar complexes, the function of PRAME may be to target
substrates for ubiquitylation by the Elongin/Cullin complex,
although the identity of these potential substrates remains
unknown.
Elongins have both nuclear and cytoplasmic functions, having
roles in protein ubiquitylation and gene transcription [24].
Interestingly, staining of HL60 cells for endogenous ELC revealed
it to be mainly cytoplasmic and at least partly associated with the
Golgi network (Fig. 3F&G), thus indicating that a major site of
interaction of PRAME and Elongins is in the cytoplasmic
compartment. CUL2 on the other hand appeared to be almost
exclusively nuclear (Fig. 3F). We did not observe any major change
in the subcellular localisation of ELB, ELC or Cul2 following
IFN/LPS treatments (data not shown), and antibody conflicts
precluded co-staining of ELC with the Golgi marker. However,
the localisation of ELB and ELC to polarised cytoplasmic foci is
consistent with Golgi/ER association. It is not yet known whether
PRAME can associate with other Cullin complexes, such as Golgi-
resident CUL3 or CUL7 proteins [25,26].
Our affinity purification experiment also identified a novel
interaction of PRAME with core histones (Table 1). Direct
interaction appears to be mediated chiefly through histone H3,
which shows strongest association with PRAME (Fig. 4C). This
result is consistent with the recent report that nuclear PRAME can
be recruited to chromatin and functions in gene regulation,
although it lacks DNA binding activity [18]. In addition, PRAME
has previously been reported to co-immunoprecipitate with the
histone methyltransferase EZH2 [17], which promotes trimethyla-
tion of H3K27. Given its interaction with Elongin BC complexes,
it is therefore conceivable that PRAME might play some role in
histone ubiquitylation, although there is currently no evidence to
support this. Several different nuclear E3 ubiquitin ligase
complexes are known to catalyse the addition of ubiquitin to core
histones [36]. This includes the CUL2 complex which promotes
monoubiquitylation of H2B at residue K120, through the
interaction of the histone with the BC-box protein BAF250b
[37]. Future studies will therefore need to focus on assessing
whether depletion or overexpression of PRAME can influence
ubiquitylation of histones or other target proteins.
Function and Regulation of PRAME
PLOS ONE | www.plosone.org 7 February 2013 | Volume 8 | Issue 2 | e58052
In conclusion, our study provides novel insights into the
functions and regulation of PRAME, as summarised in Figure 5.
We hypothesise that, like TLRs, PRAME may be upregulated in
response to encounters with microbial pathogens, and may be
involved in targeting intracellular PAMPs to the Golgi for
ubiquitylation and processing. The activation of similar cytokine
signalling pathways in cancer cells might therefore account for the
expression of PRAME in tumours, and its low levels in normal
tissues. Finally, direct interactions of PRAME with histone H3 in
addition to elongins may be important in its functions in gene
transcription. These insights will aid future efforts to establish
whether PRAME expression in tumours has roles in the initiation
or progression of haematological malignancies, and/or in immune
responses to infection.
Materials and Methods
Cell lines, reagents and transient transfections
HL60, U937, U2OS, MCF-7 and HEK293 cell lines were
purchased from the European Collection of Cell Cultures
(ECACC). HL60 and U937 leukaemic cell lines were maintained
in RPMI-1640. HEK293, U2OS and MCF-7 cells were main-
tained in Dulbecco’s modified Eagle medium. Culture medium
was supplemented with 10% foetal bovine serum, 2 mM
glutamine, 100units/ml penicillin and 100 mg/ml streptomycin
and cells were maintained at 37uC in a 5% CO2 incubator. Cell
cultures were split 24 hrs prior to treatment with 100U/ml
interferon-gamma (IFNc, AbD Serotec), 50 ng/ml Salmonella
minnesota lipopolysaccharide (LPS, Sigma-Aldrich), 5 mg/ml Bacil-
lus subtilis peptidoglycan (PGN, Sigma-Aldrich), 10 mg/ml mur-
amyl dipeptide (MDP, Sigma-Aldrich), 100 mg/ml zymosan A
(ZYM, Sigma-Aldrich) or 10 mg/ml mannan (MAN, Sigma-
Aldrich). Actinomycin D (10 mg/ml, Sigma-Aldrich) was applied
to cells 1 hr prior to other treatments.
U2OS and HEK293 cells were seeded onto coverslips 16 hrs
prior to transient transfection using CalPhosTM mammalian
transfection kit (Clontech).
Expression plasmids
PRAME-EGFP and PRAME-FLAG expression vectors [19]
were gifts from P.Gailly. Yeast two hybrid pGADT7 vectors
expressing C.elegans CUL2, ELB, ELC, ELC mutant (L47D/
L49D/Y88D/Y91D) and human ELC [38] proteins containing
haemagluttinin (HA) epitope-tags were gifts from K.Yamanaka. A
PCR fragment containing PRAME coding sequence was generated
from pCMV-Sport6-PRAME (Geneservice) using the following
primers: 59-atggaacgaaggcgtttg-39 and 59-ctagttaggcatgaaacagggg-
39. The fragment was subcloned into SmaI digested pBSKSII, to
generate pBSKSII-PRAME. pBSKSII-PRAME was digested with
BamHI and XhoI and the insert fragment was subcloned into
pGEX4T1, to generate GST-PRAME. This fragment was also
subcloned into pBTM116mod and pASV3mod [35] to generate
LexA-PRAME and VP16-PRAME, respectively. PRAME-FLAG-
His was generated by PCR from PRAME-FLAG [19] using
primers: 59-aaaaggatccgccgccatggaacgaaggcgttt g-39 and 59-
aaaactcgagctaatggtgatggtgatgatgcttgtcatcgtcatccttgtagta-39. The
insert was subcloned into the BamHI and XhoI sites in
pcDNA3.1(+).
Figure 5. Potential Functions and Regulation of PRAME. Activation of TLRs and other signalling receptors by PAMPs and cytokines associated
with infections or tumours (1) results in both transcriptional (2) and translational (3) upregulation of PRAME. Cytoplasmic PRAME can associate with
Elongin proteins located in the Golgi/ER network (4). Association of PRAME with intracellular PAMPs or other molecules (5) may facilitate their
targeting to the Golgi for modification, secretion or destruction by Elongin/Cullin Ubiquitin ligases (6). Interactions of PRAME proteins with Elongins,
Cul2 or Histone H3 in the nucleus (7) may be involved in the regulation of gene expression.
doi:10.1371/journal.pone.0058052.g005
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Polysome analysis and Northern blotting
After cycloheximide treatment of HL60 cells and preparation of
cell lysates [39], sucrose density gradients were used to separate
ribosomes into polysomal and subpolysomal complexes. Gradients
were fractionated with continuous monitoring at 254 nm, and
RNA was isolated from each fraction as described previously [40].
Northern analysis of RNA isolated from sucrose density gradients
was performed as described previously [41], using 32P-labelled
probes for full-length PRAME and actin. Activity was visualised
using a Storm825 phosphorimager (GE Healthcare) and Im-
ageQuantTL software (GE Healthcare).
Reverse transcription PCR and qPCR
RNA was extracted using EZNATM total RNA kit I (Omega
Bio-Tek). RNA was reverse transcribed using oligo(dT)12-18 and
Superscript III (Invitrogen) according to the manufacturer’s
instructions. RTqPCR was performed using Brilliant II SYBR
green qPCR mix (Stratagene) and primers: PRAME: 59-
tgctgatgaagggacaac at-39 and 59-cag cacttgaagtttccacct-39;
GAPDH: 59-aggtgaaggtcggagtcaac-39 and 59-gatga-
caagcttcccgttct-39. PCR was conducted using Mx3005P real-time
PCR system (Stratagene) with the following conditions: hot start
activation at 95uC for 10 mins followed by 40 cycles of 95uC for
30 secs, 59uC for 1 min. PCR reactions were performed in
triplicate for each sample. The threshold cycle number of PRAME
was normalised to that of GAPDH. Fold increase was calculated
using the comparative (DDCt) method, as previously described
[42].
Western blotting, antibodies and immunofluorescence
staining
Proteins were resolved on standard SDS-PAGE gels and
transferred to nitrocellulose membranes. Membranes were pre-
blocked in 3% non-fat milk in PBS prior to addition of primary
antibodies. For Western blotting, coimmunoprecipitations, and
immunofluorescence, the following antibodies were used: anti-
PRAME (ab32185, Abcam WB 1:500, IF 1:100), anti-FLAG M2
(F3165, Sigma-Aldrich WB 1:500, IF 1:100), anti-Golgi 58K
(ab27043, Abcam IF 1:100), anti-His (05–531, Millipore WB
1:1000), anti-ELB (sc11447, Santa Cruz Biotechnologies WB
1:200, IF 1:100), anti-ELC (sc1559, Santa Cruz Biotechnologies
WB 1:500, IF 1:10), anti-CUL2 (ab1870, Abcam WB 1:500, IF
1:250), anti-HA (3F10, Roche WB 1:500), anti-H2A (ab18255,
AbcamWB 1:500), anti-H2B (ab1790, AbcamWB 1:500), anti-H3
(ab1791, Abcam WB 1:1000), anti-H4 (ab7311, Abcam WB
1:500), anti-GST (Ab-2, Oncogene Research Products WB 1:500),
anti-GFP (ab6556 Abcam WB 1:500). The following horse radish
peroxidise-linked secondary antibodies were used for Western
blotting and co-immunoprecipitations at 1:5000: chicken anti-
mouse (sc2954, Santa Cruz Biotechnologies), donkey anti-goat
(30220–210, Alpha Diagnostics International), goat anti-rabbit
(sc2004, Santa Cruz Biotechnologies). For immunofluorescence,
the following secondary antibodies were used at 1:500: alexa fluor
chicken anti-mouse 488 (A21200), alexa fluor chicken anti-goat
594 (A21468) and alexa fluor chicken anti-rabbit 594 (A21442)
Invitrogen. Y2H fusion proteins in yeast cell-free extracts were
detected using anti-LexA (06–719, Millipore WB 1:1000) or anti-
HA (3F10, Roche WB 1:500).
Immunofluorescence staining and image capture was performed
using a Leica LSM510 confocal microscope essentially as
described previously [39]. U2OS, HEK293 and MCF-7 cells
were grown on glass coverslips, while non-adherent cells were
mounted on glass slides at 1000rpm for 5 minutes using a
Cytospin 4 cytocentrifuge. Representative images of IFNc/PAMP-
treated cells and PBS-treated controls immunostained with a-
PRAME antibody were quantified by manual scoring of the
percentage of cells (n = 60) showing large cytoplasmic PRAME-
containing foci.
Protein affinity purification, co-immunoprecipitation and
GST-pulldown assays
Preparation of whole cell extracts of mammalian cells was
performed by using freeze thaw cycles in cell lysis buffer with
protease inhibitors as described previously [39]. GST-PRAME
and empty pGEX-4T1 (or GST) vectors were transformed into
E.coli Rosetta cells and selected on LB plates containing ampicillin.
Single colonies were cultured to exponential phase in LB
ampicillin broth at 37uC, and GST protein expression was
induced by addition of, 0.5 mM isopropyl b-D-1-thiogalactopyr-
anoside (Merck) for 16 hrs at 20uC. Bacterial pellets were
resuspended in NTN (20 mM Tris pH8, 100 mM NaCl, 0.5%
NP40, 1 mM DTT 1X Complete EDTA-free protease inhibitor
cocktail (Roche 11836170001), sonicated and then centrifuged at
15000rpm for 40 mins at 4uC. The supernatant was added to
prewashed glutathione sepharose beads (GE Healthcare) that had
been blocked with 0.5% milk and incubated for 16 hrs at 4uC with
rotation. The beads were washed extensively in NTN buffer.
Affinity capture was performed using 1 mg whole cell extract or
15 mg purified core histones (Sigma H9250). GST, GST-PRAME
and other proteins bound to beads were resolved by SDS-PAGE
and revealed by western blotting using the antibodies described
above.
Silver staining and mass spectrometry
After protein separation by SDS-PAGE, gels were fixed with 2
washes in 40% methanol/10% acetic acid, sensitized in 30%
methanol, 0.2% sodium thiosulphate, 6.8% sodium acetate,
impregnated with 0.25% silver nitrate and developed in 2.5%
sodium carbonate, 0.15% formaldehyde, 0.003% sodium thiosul-
phate. The staining reaction was stopped in 1.46% EDTA.
Bands of interest were excised and analysed by the Cambridge
Centre for Proteomics. This involved overnight trypsin digestion of
the proteins in the gel bands followed by reverse phase liquid-
chromatography and then high mass accuracy mass spectrometry.
For identification of proteins, the MS/MS fragmentation data
were used to search the human National Centre Biological
Information database using the MASCOT search engine.
Probability-based Mowse scores were used for evaluating peptide
identifications [43]. Only those peptide matches with a Mowse
score .38 were considered significant and reported.
Yeast-two hybrid assays
Yeast transformations, yeast two-hybrid reporter assays, yeast
cell-free extract preparations for western blotting were performed
essentially as described previously [35].
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